Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS
Status:
Recruiting
Trial end date:
2026-05-03
Target enrollment:
Participant gender:
Summary
ALSUMMIT is a double-blind, randomized, placebo-controlled, multi-center, parallel, phase III
clinical trial to evaluate and confirm the efficacy and long-term safety of repeated
Lenzumestrocel (Neuronata-R® inj.) treatment.